Clinical trials: sponsored by Fujian Cancer Hospital
Solid Tumors
TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors
New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1) is a Cancer-Testis Antigen (CTA) which is expressed in various tumors. After selected the high affinity TCR gene to NY-ESO-1, the researchers insert genes into the cell…
- Trial name
- NCT05648994
- Testing
- TCR-T cells, Fludarabine, Cyclophosphamide Capsules
- Volunteers
- 30 people
- Sponsor
- Fujian Cancer Hospital
Rectal Cancer
The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy
To explore the efficacy and safety of radiotherapy followed by PD-1+ standard chemotherapy in the first-line treatment of initial unresectable rectal cancer liver metastases
- Trial name
- NCT05640726
- Testing
- PD-1, SCRT, Bevacizumab
- Volunteers
- 30 people
- Sponsor
- Fujian Cancer Hospital
Small Cell Lung Cancer, Angiogenesis
Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer
To evaluate the clinical efficacy and safety of surufatinib combined with irinotecan in the second line treatment of small cell lung cancer.
- Conditions
- Small Cell Lung Cancer, Angiogenesis, Chemotherapy Effect
- Trial name
- NCT05595889
- Testing
- Surufatinib, Irinotecan
- Volunteers
- 40 people
- Sponsor
- Fujian Cancer Hospital
Ovarian Cancer
Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
This is a single arm, multi center, exploratory clinical study to evaluate the efficacy and safety of fluzoparide combined with alpatinib as neoadjuvant therapy in patients with BRCA1/2 gene mutation or HRD gene mutation…
- Trial name
- NCT05597527
- Testing
- Fluzopari and apatinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Fujian Cancer Hospital
Hawthorn Red Combined Refractory Cancer Pain
Phase Ⅰa Clinical Study of Hawthorn Red Pigment Combined With Standard Analgesic for Refractory Cancer Pain
To evaluate the safety and tolerance of Hawthorn red pigment in the treatment of cancer pain Determine the maximum tolerated dose (MTD, if any) of Hawthorn red pigment and the recommended dose for phase II clinical study (RP2D)
- Trial name
- NCT05561023
- Testing
- Hawthorn red pigment
- Volunteers
- 14 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma
Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines
Currently, nasopharyngeal carcinoma (NPC) patients who had level II involvement with extracapsular extension (ECE), and/or had a maximum nodal axial diameter (MAD) of greater than 2cm in level II will be recommended to receive…
- Trial name
- NCT05519956
- Testing
- level Ib-covering IMRT, level Ib-sparing IMRT
- Volunteers
- 398 people
- Sponsor
- Fujian Cancer Hospital
Immunotherapy, Colorectal Cancer
TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer
To evaluate the clinical efficacy and safety of TAS-102 combined with bevacizumab and tislelizumab in third-line or above treatment in patients with advanced colorectal adenocarcinoma with liver metastasis.
- Trial name
- NCT05314101
- Testing
- Tislelizumab, bevacizumab, TAS-102
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fujian Cancer Hospital
Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology, The TNM (8th) Phase is IV
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy
Efficacy and safety of Dalpiciclib combined with third-generation EGFR-TKI in patients with advanced EGFR-mutated non-small cell lung cancer with meningeal metastasis after third-generation TKI and platinum-containing chemotherapy
- Conditions
- Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology, The TNM (8th) Phase is IV, With EGFR Mutations, Meningeal Progression Occurred After Previous Platinum-containing Two-drug Chemotherapy and Third-generation EGFR-TKI Treatment
- Trial name
- NCT05497076
- Volunteers
- 9 people
- Sponsor
- Fujian Cancer Hospital
Colon Cancer
To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer
The objective is to investigate the efficacy and safety of Envafolimab combined with XELOX in neoadjuvant therapy for locally advanced colon cancer
- Trial name
- NCT05335460
- Testing
- Envafolimab
- Volunteers
- 36 people
- Sponsor
- Fujian Cancer Hospital
Metastatic Colorectal Cancer
Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer
Thalidomide has both anti-angiogenesis and antiemetic effects, and its combined use with TAS-102 may reduce the gastrointestinal reactions associated with TAS-102, while enhancing antitumor efficacy and reducing the side effects…
- Trial name
- NCT05266820
- Testing
- Thalidomide, TAS-102
- Where
- 6 sites in China
- Volunteers
- 120 people
- Sponsor
- Fujian Cancer Hospital
Advanced Non-small-cell Lung Cancer
Tislelizumab as Cross-line Treatment for Advanced NSCLC
This study is a single-arm, prospective, open phase II clinical study, exploring the efficacy and safety for advanced non-small cell lung cancer after progression of first-line Tislelizumab combined with chemotherapy and…
- Trial name
- NCT05192681
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Fujian Cancer Hospital
Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma
PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
The purpose of this study is to explore the efficacy and safety of compare the efficacy and safety of PD-1 inhibitor and chemotherapy（treatment group） with chemoradiotherapy（control group） in neoadjuvant treatment of resectable…
- Trial name
- REVO (NCT05007145)
- Testing
- PD-1 inhibitor, Albumin-Bound Paclitaxel, Cisplatin
- Where
- 6 sites in China
- Volunteers
- 92 people
- Sponsor
- Fujian Cancer Hospital
Colorectal Cancer Stage II, Colorectal Cancer Stage III
the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer
The purpose of this study was to observe the relationship between ctDNA as a molecular marker of colorectal cancer and the risk of postoperative recurrence.
- Trial name
- NCT05131243
- Testing
- Chemotherapy time
- Volunteers
- 100 people
- Sponsor
- Fujian Cancer Hospital
Advanced Colorectal Cancer
Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study
A phase II study to assess the efficacy and safety of Surufatinib combined with Sintilimab as a second-line treatment in patients with advanced MSS-Type CRC.
- Trial name
- NCT04764006
- Testing
- Surufatinib
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Fujian Cancer Hospital
Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma
Study of FMT Combined With Nivolumab in Gastric Cancer
This study is a single-arm, single center study. The purpose of this study is to evaluate the efficacy and safety of FMT capsules XBI-302 combined with Nivolumab in the treatment of anti-PD-1/L1 resistant gastric cancer.
- Conditions
- Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma, Esophagus Adenocarcinoma
- Trial name
- NCT05001360
- Testing
- XBI-302 + Nivolumab
- Where
- China
- Sponsor
- Fujian Cancer Hospital
Surgery
Short-term Outcomes of SILS+1 Versus CLS for Distal Gastric Cancer
To evaluate the short-term outcomes of single-incision plus one-port laparoscopic surgery (SILS + 1) versus conventional laparoscopic surgery(CLS) for distal gastric cancer whose clinical stage was cT1-3N0-2M0
- Trial name
- NCT05035446
- Testing
- single-incision plus one-port laparoscopic surgery, conventional laparoscopic surgery
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fujian Cancer Hospital
Cancer Pain
Effects of Mobile Medicine on Cancer Patients
With the existing medical system and insufficient medical resources in China, we developed a mini program. a pain management mini app can be useful and appreciated by patients and health care professionals, making it a good…
- Trial name
- NCT05049811
- Testing
- mini program, conventional pharmaceutical care
- Volunteers
- 200 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma
Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma
A prospective, single-arm,mutil-center study to assess the efficacy and safety of Surufatinib combined with Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.
- Trial name
- NCT04955886
- Testing
- Surufatinib(HMPL-012)
- Where
- 2 sites in China
- Volunteers
- 14 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma
Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPC
The purpose of this study was to evaluate its rationality in real-world data and provide clinical evidence for the refinement of nodal CTV delineation in nasopharyngeal carcinoma(NPC).
- Trial name
- NCT04745741
- Testing
- IB-positive group
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fujian Cancer Hospital
Malignant Neoplasm of Stomach Stage IV
POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC
The aim of this study was to compare the efficacy and safety of POF, FOLFOX, and FOLFOX plus paclitaxel(ip) as first-line treatment in AGC a phase II clinical trial.
- Trial name
- NCT02845908
- Testing
- POF, FOLFOX, FOLFOX plus PAC(ip)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Fujian Cancer Hospital